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ABSTRACT
Background: As the number of minimally invasive and
laparoscopic procedures increases, hemostatic agents are
becoming more popular as a means of achieving rapid
hemostasis.
Case Report: The patient is a 61-year-old woman who
underwent a laparoscopic supracervical hysterectomy.
FloSeal Hemostatic Matrix (Baxter Healthcare, Deerfield
Illinois) was used at the conclusion of the procedure.
Results: Pathology unexpectedly revealed high-grade
leiomyosarcoma of the uterus. The patient then presented
to our facility for consultation and was scheduled for
robotic trachelectomy and lymphadenectomy. Laparos-
copy revealed nodular lesions throughout the abdomen
and pelvis. Biopsies were performed and the case
aborted. Final pathology however showed caseating for-
eign body giant cell granulomata in all specimens. No
malignancy was found. The patient then underwent ex-
ploratory laparotomy, trachelectomy, and a staging pro-
cedure. All pathology specimens and pelvic washings
were negative for malignancy.
Conclusions: Use of gelatin-thrombin hemostatic agents
may elicit a foreign body reaction leading to large giant
cell granulomata. In this case, the presence of these gran-
ulomata mimicked metastatic disease.
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INTRODUCTION
Egyptians used various high-temperature cautery, waxes,
and poultices to obtain hemostasis, Native Americans ap-
plied scrapings from animal hides to wounds, and the
Greek scholar Hippocrates described the use of high-
temperature cautery and various topical hemostatic agents
to stop bleeding. In the modern era, fibrin used as a
topical hemostatic agent was introduced in the early
1900s. In 1940, the use of Gelfoam in neurological proce-
dures was popularized. More recently, multiple new prod-
ucts have entered the market. FloSeal Hemostatic Matrix
(Baxter Healthcare, Deerfield, Illinois) consists of a bo-
vine-derived gelatin matrix component, a human-derived
thrombin component, applicator tips, and several mixing
accessories. It is approved by the FDA for broad applica-
tions in surgical care as an adjunct to hemostasis when
control of bleeding by ligature or conventional proce-
dures is ineffective or impractical. There is scant literature
regarding complications with the use of FloSeal.
CASE REPORT
The patient is a 61-year-old female with a 2-year history of
postmenopausal bleeding. She underwent hysteroscopic
resection of a submucousal leiomyoma at the age of 59.
She presented again for postmenopausal bleeding. An
ultrasound showed a large 5-cm subserosal leiomyoma
and several new submucosal leiomyomata. An endome-
trial biopsy was negative for malignancy. Cervical cytol-
ogy examinations including human papilloma virus test-
ing were negative. The patient underwent a laparoscopic
supracervical hysterectomy and bilateral salpingo-oopho-
rectomy. The specimen was removed by morcellation.
According to the operative report, FloSeal was applied to
the cervical stump for adhesion prevention. The specimen
weighed 229 grams and showed fragments of intermedi-
ate to high-grade leiomyosarcoma. Trachelectomy and a
staging procedure were advised soon after the initial sur-
gery, but the patient desired a second opinion.
At our facility, the patient was offered trachelectomy and
robotic-assisted laparoscopic staging versus exploratory
laparotomy and staging. She opted for the robotic ap-
proach. Upon introduction of the laparoscope, extensive
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CASE REPORTnodular lesions throughout the abdomen and pelvis were
noted, involving the bowel, omentum, abdominal wall,
and cervical stump (Figures 1, 2, 3). Several biopsies
were obtained, and the case was aborted assuming ad-
vanced metastatic leiomyosarcoma. The final pathology
revealed caseating giant cell granulomata without evi-
dence of malignancy (Figures 4, 5, 6).
The patient subsequently underwent exploratory laparot-
omy, trachelectomy, and staging. Operative findings were
unchanged from the previous procedure. The pathology
revealed extensive caseating granulomata, a lower uterine
segment and cervix with leiomyomata, but no evidence of
malignancy. All lymph nodes and biopsies were negative.
The postoperative course was uncomplicated. Adjuvant
chemotherapy was offered but the patient declined.
DISCUSSION
FloSeal Matrix Hemostatic Agent (Baxter HealthCare,
Deerfield, IL) is composed of thrombin and a proprietary
gelatin matrix that is manufactured by extracting collagen
from bovine corneal tissue. The collagen then undergoes
gelatinization and cross linking/stabilization with glutar-
aldehyde. This compound is ground into 500-mt o
600-m particles. The thrombin component, Thrombin-
JMI (King Pharmaceuticals, Inc., Bristol, TN), is of bovine
origin and is supplied as a sterile freeze-dried powder that
is reconstituted in 0.9% sodium chloride and mixed with
the gelatin matrix in the operating room just before use.
Bovine thrombin directly activates fibrinogen and con-
verts it into fibrin monomers, bypassing the intrinsic and
extrinsic systems.1
Because FloSeal contains no fibrinogen, contact with
blood is required for thrombin to convert endogenous
fibrinogen to fibrin. The combination of thrombin and
gelatin matrix creates a granular hemostat that uses both
active and mechanical components to achieve hemosta-
sis.2 As blood percolates through the matrix in the pres-
ence of bleeding, the granules swell approximately 20%
within 10 minutes, conforming to the shape of the wound
and forming fibrin polymers. Gelatin matrix is therefore
used best as a pure hemostatic agent, not as tissue glue,
urinary tract sealant, or for adhesion prevention. The ma-
trix is applied to a source of bleeding and kept in place for
approximately 2 minutes. Excess FloSeal should be re-
moved by gentle irrigation. FloSeal is resorbed by the
Figure 2. Caseating granuloma caused by hemostatic agent
posing as leiomyosarcoma laparoscopic image of lesions involv-
ing right abdominal wall peritoneum.
Figure 3. Caseating granuloma caused by hemostatic agent
posing as leiomyosarcoma laparoscopic image of lesions involv-
ing cervical stump, omentum and peritoneum overlying bladder.
Figure 1. Caseating granuloma caused by hemostatic agent
posing as leiomyosarcoma laparoscopic image of lesions involv-
ing cul de sac and right pelvic sidewall.
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frame of normal wound healing.3
Gelatin-based hemostatic agents may serve as a nidus for
infection and abscess formation and have been reported
to potentiate bacterial growth. Giant cell granulomas, as
presented in this case, have been observed at implant sites
when used in the brain.4 In a case reported by Nakajima
et al,5 granulomatous masses secondary to microfibrillar
collagen hemostat (Avitene, Davol, Inc, Cranston, RI)
were thought to be metastatic mucinous cystadenocarci-
noma.
CONCLUSION
In the case presented, giant cell granulomas secondary to
the use of FloSeal Hemostatic Matrix were mistaken for
metastatic leiomyosarcoma. This led to cancellation of the
planned procedure and need for a second procedure. This
product should be used only when control of bleeding is
needed and conventional procedures are ineffective or
impractical. It should not be used as a prophylactic mea-
sure or for adhesion prevention. When using all gelatin-
based hemostatic agents, excess material, not incorpo-
rated in the clot, should be removed to prevent foreign
body reactions.
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Figure 4. Caseating granuloma caused by hemostatic agent low
power image of caseating granuloma.
Figure 5. Caseating granuloma caused by hemostatic agent
multinucleated giant cell within granulomata.
Figure 6. Caseating granuloma caused by hemostatic agent
pathology showing foreign material within granuloma.
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